Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Adenocarcinoma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5 Fallopian Tube Neoplasms 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Neoplasms 2 Advanced Solid Tumor 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pancreatic Adenocarcinoma 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Glioma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Advanced Solid Tumor, Adult 1

Interventions

tocilizumab 1 selicrelumab 1 niraparib 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Panitumumab 1 PEGPH20 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Leucovorin 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Bevacizumab 1 4-fluorobenzoyl-TN-14003 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡